158 related articles for article (PubMed ID: 30644334)
1. Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation.
Christen D; Sohlbach K; Metzelder SK; Wollmer E; Hoeffkes HG; Naumann R; Burchardt A; Rummel M; Trenker C; Dohse M; Mack E; Klameth A; Mann C; Kostrewa P; Brendel C; Wündisch T; Neubauer A; Wilhelm C; Burchert A
Leuk Lymphoma; 2019 Aug; 60(8):2056-2061. PubMed ID: 30644334
[TBL] [Abstract][Full Text] [Related]
2. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
Sarina B; Mariotti J; Bramanti S; Morabito L; Crocchiolo R; Rimondo A; Tordato F; Pocaterra D; Casari E; De Philippis C; Carlo-Stella C; Santoro A; Castagna L
Transpl Infect Dis; 2018 Aug; 20(4):e12906. PubMed ID: 29668124
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients.
Miceli MH; Churay T; Braun T; Kauffman CA; Couriel DR
Mycopathologia; 2017 Jun; 182(5-6):495-504. PubMed ID: 28124219
[TBL] [Abstract][Full Text] [Related]
4. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Invasive Mold Infections and Implications for Choice of Prophylaxis after Allogeneic Stem Cell Transplantation.
Blennow O; Remberger M; Törlén J; Szakos A; Ljungman P; Mattsson J
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1684-1689. PubMed ID: 27311967
[TBL] [Abstract][Full Text] [Related]
6. Risks and outcomes of invasive fungal infections in pediatric allogeneic hematopoietic stem cell transplant recipients receiving fluconazole prophylaxis: a multicenter cohort study by the Turkish Pediatric Bone Marrow Transplantation Study Group.
Hazar V; Karasu GT; Uygun V; Öztürk G; Kiliç SÇ; Küpesiz A; Daloglu H; Aksoylar S; Atay D; Ince EÜ; Karakükçü M; Özbek N; Tayfun F; Kansoy S; Özyürek E; Akçay A; Gürsel O; Haskologlu S; Kaya Z; Yilmaz S; Tanyeli A; Yesilipek A
Med Mycol; 2019 Feb; 57(2):161-170. PubMed ID: 29608706
[TBL] [Abstract][Full Text] [Related]
7. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors of probable and proven invasive fungal infection in adult patients receiving allogeneic hematopoietic stem cell transplantation.
Liu YC; Chien SH; Fan NW; Hu MH; Gau JP; Liu CJ; Yu YB; Liu CY; Hsiao LT; Liu JH; Chiou TJ; Chen PM; Tzeng CH
J Microbiol Immunol Infect; 2016 Aug; 49(4):567-74. PubMed ID: 25735797
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
[TBL] [Abstract][Full Text] [Related]
10. [The clinical characteristic and risk factors for the incidence of invasive fungal infection in patients following allogeneic hematopoietic stem cell transplantation].
Zhang Y; Liu C; Liu QF; Sun J; Fan ZP; Xu D; Jiang QL
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(40):2814-7. PubMed ID: 20137659
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting.
Busca A; Passera R; Maffini E; Festuccia M; Brunello L; Dellacasa CM; Aydin S; Frairia C; Manetta S; Butera S; Iovino G; Giaccone L; Sorror M; Storb R; De Rosa FG; Bruno B
Bone Marrow Transplant; 2018 Oct; 53(10):1304-1310. PubMed ID: 29654289
[TBL] [Abstract][Full Text] [Related]
12. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
[TBL] [Abstract][Full Text] [Related]
13. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
14. A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation.
Jorgenson MR; Descourouez JL; Marka NA; Leverson GE; Smith JA; Andes DR; Fernandez LA; Foley DP
Transpl Infect Dis; 2019 Oct; 21(5):e13156. PubMed ID: 31390109
[TBL] [Abstract][Full Text] [Related]
15. The Role of Fluconazole Prophylaxis Regimen and the Regimes Chosen by the Patient’s Risk of Fungal Infection in Reducing the Infection Rate after Bone Marrow Transplantation.
Pourghasemian M; Mehdizadeh M; Hajfathali A; Habibzadeh A; Hosseini MH
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1543-1546. PubMed ID: 29936729
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation.
Herity LB; Cruz OA; Aziz MT
J Oncol Pharm Pract; 2022 Jun; 28(4):794-804. PubMed ID: 33906508
[TBL] [Abstract][Full Text] [Related]
17. Invasive fungal disease is associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant: a single center, retrospective study.
Jin H; Fan Z; Huang F; Chai Y; Xuan L; Lin R; Xu N; Ye J; Sun J; Liu Q
Infection; 2019 Apr; 47(2):275-284. PubMed ID: 30734248
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
19. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study.
Marty FM; Lee SJ; Fahey MM; Alyea EP; Soiffer RJ; Antin JH; Baden LR
Blood; 2003 Oct; 102(8):2768-76. PubMed ID: 12855583
[TBL] [Abstract][Full Text] [Related]
20. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients.
Martino R; Subirá M; Rovira M; Solano C; Vázquez L; Sanz GF; Urbano-Ispizua A; Brunet S; De la Cámara R;
Br J Haematol; 2002 Feb; 116(2):475-82. PubMed ID: 11841455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
